Skip to main content

Security report for ibsaczechia.cz

IBSA PHARMA s.r.o. · Healthcare · Czech Republic

Medium risk. 7 critical or high findings in GDPR outside view, Email security and 2 other checks.

Security score

64/100

Risk levelMedium

0–100, higher is better. How it is calculated

IBSA PHARMA s.r.o. is a Czech subsidiary of the Swiss multinational pharmaceutical group IBSA, founded in 1945. The company operates globally with products available in over 90 countries and 20 subsidiaries worldwide. The website serves as a corporate portal providing information about the company, its pillars, therapeutic areas, and corporate documents including sustainability reports. The target audience includes healthcare professionals and partners in the pharmaceutical industry. Technically, the website uses modern JavaScript libraries such as jQuery, Google Analytics, and Google Tag Manager for tracking, along with OneTrust for cookie consent management. The site is mobile optimized and has a clear navigation structure, though no CMS or hosting provider details are explicitly detected. Performance is moderate with good SEO and basic accessibility features. Security posture is adequate with HTTPS and cookie consent mechanisms in place, but lacks explicit HTTP security headers and publicly available security or incident response policies. No vulnerabilities or exposed sensitive data were detected in the HTML content. WHOIS data is unavailable, which reduces domain trustworthiness, but the website content and external links to known IBSA group subsidiaries support legitimacy. Overall, the site is professional and trustworthy but would benefit from enhanced security headers, explicit incident response information, and improved accessibility compliance to strengthen its security and compliance posture.

Scanned

NIS2 and GDPR posture

GDPR outside view
40/ 100 · High
Checks completed
7of 7

NIS2 Art. 21(2)

  1. (a) Risk analysis and security policies: Not visible from outside
  2. (b) Incident handling: One indicator
  3. (c) Business continuity, backups and crisis management: Not visible from outside
  4. (d) Supply chain security: Not visible from outside
  5. (e) Secure acquisition, development and maintenance, including vulnerability handling: Partly checked
  6. (f) Assessing the effectiveness of security measures: Not visible from outside
  7. (g) Cyber hygiene and security training: Not visible from outside
  8. (h) Cryptography and encryption: Partly checked
  9. (i) HR security, access control and asset management: One indicator
  10. (j) Multi-factor authentication and secured communications: Not visible from outside

This scan rated NIS2 with an earlier keyword method that is no longer shown; rescan for the per-article view. Risk management, continuity, supply chain, training, MFA, management oversight (Art. 20) and incident reporting (Art. 23) need internal evidence, and Guard cannot tell whether NIS2 applies to this organisation.

GDPR is indicative only, based on publicly visible signals: Articles 7, 12, 13 and 32 of Regulation (EU) 2016/679 and Article 5(3) of the ePrivacy Directive. Not a certification or legal assessment.

Priority findings

7 findings rated critical or high. Fix these first.

  1. GDPR outside view

    These are the privacy signals visitors and data protection authorities look for under GDPR.

    • Critical

      EU business without adequate privacy measures

      EU businesses are subject to strict GDPR requirements

      What to do: Implement comprehensive GDPR compliance including privacy policy, cookie consent, and data protection measures

    • High

      No Privacy Policy found

      GDPR requires a clear and accessible privacy policy

      What to do: Add a comprehensive privacy policy page and link to it prominently

    • High

      Third-party services without privacy policy

      Detected services: Google Analytics, Facebook, Google APIs

      What to do: Document all third-party data sharing in your privacy policy

  2. Email security

    SPF, DKIM and DMARC stop others sending email that looks like it comes from your domain, a common route to phishing and invoice fraud.

    • Critical

      No email authentication configured

      Domain is vulnerable to email spoofing

      What to do: Implement SPF, DKIM, and DMARC immediately

  3. Security headers

    Security headers are instructions your web server sends to every visitor’s browser. Missing ones leave visitors more exposed to attacks such as clickjacking and injected scripts.

    • High

      Missing X-Frame-Options header

      Prevents clickjacking attacks

      What to do: Add "X-Frame-Options: DENY" or "X-Frame-Options: SAMEORIGIN"

Need hands-on remediation? Email guard@offseq.com

Keep watching ibsaczechia.cz

This scan found 22 issues across 6 checks. Monitoring re-runs those checks daily, emails you when something material changes and records each fix, so you can show progress.

Daily monitoring

Recommended

€25per month

  • TLS certificates and expiry
  • DNS records
  • SPF, DKIM and DMARC
  • Security headers
  • GDPR and NIS2 posture
  • Exposed services
  • Third-party trackers
  • Security score drift

Email alerts on material changes and an exportable JSON history of every change.

Billed monthly to your card. Cancel anytime. See sample alerts.

Full report

€39.90one-time

  • The complete analysis as a PDF you can cite
  • Email delivery with an unlock code
  • Lifetime access to this report

Prices incl. 21% VAT. Secure checkout by Mollie; sold by SEQ SIA, Latvia.

Results by check

Each check with its score, findings and the evidence it collected.

How this score is calculated

The security score runs 0–100, higher is better. It is the plain average of the security checks that completed in this scan, each counted equally. A check that could not run is left out: it counts neither as a pass nor as a fail.

Counted in this score

SSL/TLS
82
Security headers
45
Email security
40
DNS health
75
Network security
100
GDPR outside view
40
Average
64

Not counted

  • NIS2 outside view: Re-weights evidence from the TLS, email, DNS, network and hygiene checks, so counting it would count that evidence twice. Shown on its own.
  • OffSeq Observations: An AI reading of the site, useful context but not reproducible evidence. Shown on its own.

Findings that cap the score at 49

Each of these is serious on its own, so while any is present the site cannot rate better than high risk, however good the other checks are.

  • The certificate is not trusted by browsers
  • The website is not served over HTTPS
  • A database, remote desktop, file-sharing or Telnet service is reachable from the internet
  • The page loads a script from a compromised source
  • The domain registration has expired
  • SPF authorises every server to send mail as the domain

Partial scans

When the site blocks Guard or most checks cannot run, the score covers only the checks that ran (usually DNS and email), is capped at 75 and is shown as partial, without a risk level.

Risk levels

  • Critical0–25
  • High26–49
  • Medium50–75
  • Low76–100

Technical appendix

Business context, site observations and technical notes gathered during the scan, and the standards behind each reference.

Business context

Business profile

IBSA PHARMA s.r.o. is positioned as a key player in the pharmaceutical sector within the Czech Republic and as part of the larger IBSA Group multinational. The company leverages a broad geographic footprint with subsidiaries across Europe, Asia, and the Americas. Its business model focuses on pharmaceutical manufacturing and distribution across multiple therapeutic areas including reproductive medicine, endocrinology, pain management, and dermatology. The company emphasizes sustainability and corporate responsibility, as evidenced by published reports and dedicated website sections. The presence of multiple country-specific domains indicates a strong regional market strategy. The website content and structure reflect a mature business with established market presence and professional branding.

Security posture

The website demonstrates a moderate security maturity level with HTTPS enabled and a cookie consent mechanism compliant with GDPR. However, the absence of key HTTP security headers such as Content-Security-Policy, X-Frame-Options, and Strict-Transport-Security reduces the overall security posture. No incident response or security policy information is publicly available, which is a gap in transparency and readiness. The use of third-party scripts like Google Analytics and OneTrust is standard but requires ongoing monitoring for vulnerabilities. No exposed sensitive data or obvious vulnerabilities were found in the HTML content. The lack of WHOIS data is a concern but does not necessarily indicate malicious intent given the corporate nature of the site and its external links to verified IBSA domains.

Recommendations

  1. Implement comprehensive HTTP security headers including CSP, HSTS, and X-Frame-Options to enhance protection against common web attacks.
  2. Publish explicit security and incident response policies on the website to improve transparency and preparedness.
  3. Conduct regular security audits of third-party scripts and dependencies to mitigate risks from vulnerable libraries.
  4. Improve website accessibility compliance to meet WCAG standards and enhance user experience for all visitors.
  5. Obtain and maintain accurate WHOIS registration data to improve domain trustworthiness and legitimacy.

Contact details published on the site

Addresses
Legal name
IBSA PHARMA s.r.o.
Site observations

Automated reading of the public site. Ratings are indicative.

Business

Company
IBSA PHARMA s.r.o.
Description
IBSA Group je švýcarská nadnárodní farmaceutická společnost se sídlem ve švýcarském Luganu. IBSA (Institut Biochimique SA) je švýcarská nadnárodní farmaceutická společnost založená v roce 1945 v Luganu. Produkty jsou přítomny ve více než 90 zemích na 5 kontinentech s 20 pobočkami v Evropě, Číně a Spojených státech.
Key services
Pharmaceutical products, Therapeutic solutions in multiple medical areas, Corporate and sustainability reporting
Content quality
good
Branding
consistent

Technology

Stack
jQuery 3.7.1, Google Analytics, Google Tag Manager, OneTrust Cookie Consent
Performance
moderate
Mobile
good
Accessibility
basic
SEO
good

Security

Observed score
70/100
Good practices seen
  • Cookie consent mechanism implemented
  • No exposed sensitive data in HTML

Analytics and tracking

Services
Google Analytics, Google Tag Manager
Tracking level
moderate
Privacy practices
good

Advertising

Marketing tools
OneTrust Cookie Consent
Transparency
basic

Site quality

Design
good
User experience
good
Content relevance
good
Navigation
good
Professionalism
good
Trustworthiness
high

Key observations

  1. Website is a corporate pharmaceutical site for IBSA Czechia, part of IBSA Group.
  2. WHOIS data unavailable, limiting domain registration trust analysis.
  3. Privacy and cookie policies are present and GDPR compliant.
  4. No explicit security headers detected in HTML content.
  5. Uses Google Analytics and Tag Manager for tracking.
  6. Cookie consent implemented via OneTrust.
  7. Multiple external links to IBSA group subsidiaries and partner sites.
  8. No evidence of adult or questionable content.
  9. Site is accessible without WAF or security challenge blocking.
Technical notes

Notes

The website uses a modern front-end stack with jQuery 3.7.1, Google Analytics, Google Tag Manager, and OneTrust for cookie consent. The HTML structure is well-organized with responsive design elements and lazy loading for images. SEO is supported by meta tags and Open Graph data, though no JSON-LD structured data was detected. The site lacks a detectable CMS or hosting provider information. Performance is moderate with some optimization opportunities. Accessibility features are basic but could be improved. The site includes multiple external links to verified IBSA group subsidiaries, indicating a well-integrated corporate web presence.
Standards and sources

Reference chips under each finding point to the standard, regulation or specification the finding relates to. They are taken from the official datasets below and mapped conservatively: a finding with no defensible link shows none. NIS2 and GDPR references mark where a finding is relevant evidence, not a compliance verdict. Implementing Regulation (EU) 2024/2690 binds digital infrastructure and digital service providers; for other entities it is the most detailed public reading of the Article 21 measures. WCAG, EN 301 549, European Accessibility Act and Web Accessibility Directive references name the requirement an automated accessibility rule relates to; they are not a conformance verdict.

Retrieved 2026-10-25

Reviews of this site

Share your experience with ibsaczechia.cz. Every review is verified by email and published after moderation.

Overall rating
Select a rating
4000 characters remaining

We’ll email you to confirm your review and keep your details private.

Community rating

No published reviews yet. Be the first to review ibsaczechia.cz.

Feedback on this report

Rate this report, add an optional comment, and tell us if you want a security specialist to follow up.

Overall report quality
Select a rating
2000 characters remaining

We only use your feedback to improve Guard reports. Contact details are never shared.